| Target Molecule | c(RGDfK) |
| Synonyms | Cyclo(-RGDfK), Cyclo(Arg-Gly-Asp-D-Phe-Lys), cyclic RGD peptide, αvβ3 integrin ligand |
| CAS Number | 161552-03-0 |
| Sequence | Cyclo(-Arg-Gly-Asp-D-Phe-Lys-) (head-to-tail cyclic pentapeptide) |
| One-Letter | cyclo(-RGDfK) (f = D-Phe) |
| Cyclization | Head-to-tail backbone amide (homodetic cyclic pentapeptide; no disulfide) |
| Molecular Formula | C₂₇H₄₁N₉O₇ |
| Molecular Weight | 603.7 |
| Service Category | Custom Synthesis / Pharmaceutical Peptide R&D |
| Synthesis Purity | Customizable (e.g., ≥95%, ≥98%, ≥99% by HPLC) |
| Appearance | White to off-white lyophilized powder |
| Counter Ion | Trifluoroacetate (TFA) or Custom Acetate Options |
| Synthesis Technology | Solid-Phase Peptide Synthesis (SPPS) with Head-to-Tail Cyclization |
| Modification Options | Lysine ε-amine conjugation, fluorescent labeling, chelator attachment |
| Available Scale | Milligram (R&D) to Kilogram (Commercial Manufacturing) |
| Analytical Data | Comprehensive COA, HPLC, MS provided per batch |
| Usage | Raw material synthesized strictly for laboratory research, pharmaceutical R&D, and industrial manufacturing. Not a finished drug. |
c(RGDfK) (CAS 161552-03-0) is a head-to-tail cyclic pentapeptide featuring the Arg-Gly-Asp motif and a D-phenylalanine residue. We synthesize this specific sequence as a high-purity raw material for integrin αvβ3-targeted research and pharmaceutical development.
We utilize optimized solid-phase peptide synthesis (SPPS) followed by precise head-to-tail backbone amide cyclization. This platform ensures highly efficient amino acid coupling and strict control over deletion impurities, yielding batches that meet rigorous HPLC purity specifications.
Yes. While the standard structure provides an accessible lysine side-chain amine handle, our modification services can utilize this ε-amine for targeted conjugation with fluorescent dyes, chelators, radiolabels, or carriers without interfering with the binding motif.
Our infrastructure transitions seamlessly from milligram-scale laboratory batches to kilogram-scale commercial production. We maintain rigorous batch-to-batch consistency essential for industrial-scale pharmaceutical formulation.
We serve as a strategic technical partner. Our team assists with sequence stability testing, impurity profiling, and the provision of complete analytical documentation to accelerate downstream project timelines.
c(RGDfK), defined by the head-to-tail cyclic sequence cyclo(-Arg-Gly-Asp-D-Phe-Lys-), is a widely utilized scaffold for building αvβ3 integrin-targeted imaging agents and delivery systems. Synpeptide provides comprehensive synthetic solutions for this target molecule, leveraging our technical expertise to support industrial pharmaceutical R&D.
Through our established peptide synthesis platform, we achieve efficient coupling of the pentamer sequence via optimized Solid-Phase Peptide Synthesis (SPPS). We execute precise head-to-tail backbone amide cyclization without disulfide bonds, strictly controlling impurity profiles during manufacturing to ensure the final c(RGDfK) material meets exact purity specifications (routinely ≥98% via HPLC). This rigorous process control guarantees the reproducibility required for advanced research and commercial applications.
A key feature of c(RGDfK) is the availability of the lysine side-chain amine handle for selective conjugation. To meet specific research or formulation requirements, we offer extensive peptide modification services. Formulators can request targeted attachment of fluorescent dyes, chelators for radiolabels, or drug carriers to the lysine ε-amine, enabling the creation of advanced targeted delivery systems and molecular probes.
Scaling a cyclic peptide from benchtop research to commercial application demands stable manufacturing protocols. We facilitate efficient large-scale peptide synthesis for c(RGDfK), managing the transition from milligram screening batches to kilogram-scale production. Our large-scale infrastructure ensures a continuous, reliable supply chain for pharmaceutical developers, supported by complete analytical documentation including COA, MS, and HPLC data.
Beyond raw material manufacturing, we act as a technical partner for one-stop cyclic peptide R&D. We actively assist clients in sequence stability assessments, impurity profiling, and degradation analysis. Whether integrating c(RGDfK) into targeted imaging research or developing novel therapeutic conjugates, our engineering team provides the precise analytical data and synthetic capacity required to execute complex R&D projects efficiently.
